The R.O.A.D. to clinical trial emulation
Authors:
Dimitris Bertsimas,
Angelos G. Koulouras,
Hiroshi Nagata,
Carol Gao,
Junki Mizusawa,
Yukihide Kanemitsu,
Georgios Antonios Margonis
Abstract:
Observational studies provide the only evidence on the effectiveness of interventions when randomized controlled trials (RCTs) are impractical due to cost, ethical concerns, or time constraints. While many methodologies aim to draw causal inferences from observational data, there is a growing trend to model observational study designs after RCTs, a strategy known as "target trial emulation." Despi…
▽ More
Observational studies provide the only evidence on the effectiveness of interventions when randomized controlled trials (RCTs) are impractical due to cost, ethical concerns, or time constraints. While many methodologies aim to draw causal inferences from observational data, there is a growing trend to model observational study designs after RCTs, a strategy known as "target trial emulation." Despite its potential, causal inference through target trial emulation cannot fully address the confounding bias in real-world data due to the lack of randomization. In this work, we present a novel framework for target trial emulation that aims to overcome several key limitations, including confounding bias. The framework proceeds as follows: First, we apply the eligibility criteria of a specific trial to an observational cohort. We then "correct" this cohort by extracting a subset that matches both the distribution of covariates and the baseline prognosis of the control group in the target RCT. Next, we address unmeasured confounding by adjusting the prognosis estimates of the treated group to align with those observed in the trial. Following trial emulation, we go a step further by leveraging the emulated cohort to train optimal decision trees, to identify subgroups of patients with heterogeneity in treatment effects (HTE). The absence of confounding is verified using two external models, and the validity of the treatment recommendations is independently confirmed by the team responsible for the original trial we emulate. To our knowledge, this is the first framework to successfully address both observed and unobserved confounding, a challenge that has historically limited the use of randomized trial emulation and causal inference. Additionally, our framework holds promise in advancing precision medicine by identifying patient subgroups that benefit most from specific treatments.
△ Less
Submitted 4 December, 2024;
originally announced December 2024.
The R.O.A.D. to precision medicine
Authors:
Dimitris Bertsimas,
Angelos G. Koulouras,
Georgios Antonios Margonis
Abstract:
We propose a prognostic stratum matching framework that addresses the deficiencies of Randomized trial data subgroup analysis and transforms ObservAtional Data to be used as if they were randomized, thus paving the road for precision medicine. Our approach counters the effects of unobserved confounding in observational data by correcting the estimated probabilities of the outcome under a treatment…
▽ More
We propose a prognostic stratum matching framework that addresses the deficiencies of Randomized trial data subgroup analysis and transforms ObservAtional Data to be used as if they were randomized, thus paving the road for precision medicine. Our approach counters the effects of unobserved confounding in observational data by correcting the estimated probabilities of the outcome under a treatment through a novel two-step process. These probabilities are then used to train Optimal Policy Trees (OPTs), which are decision trees that optimally assign treatments to subgroups of patients based on their characteristics. This facilitates the creation of clinically intuitive treatment recommendations. We applied our framework to observational data of patients with gastrointestinal stromal tumors (GIST) and validated the OPTs in an external cohort using the sensitivity and specificity metrics. We show that these recommendations outperformed those of experts in GIST. We further applied the same framework to randomized clinical trial (RCT) data of patients with extremity sarcomas. Remarkably, despite the initial trial results suggesting that all patients should receive treatment, our framework, after addressing imbalances in patient distribution due to the trial's small sample size, identified through the OPTs a subset of patients with unique characteristics who may not require treatment. Again, we successfully validated our recommendations in an external cohort.
△ Less
Submitted 2 November, 2023;
originally announced November 2023.
